RSRicardo A. M. Serafim

Ricardo A. M. Serafim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ricardo A. M. Serafim has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors

    by Xiaojun Julia Liang, Claudia Albertini, Thales Kronenberger, Ekaterina Shevchenko, Alexander Rasch, Benedict-Tilman Berger, Martin Schwalm, Lena Marie Berger, Andreas Krämer, Ricardo A. M. Serafim, et al.

    The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family comprises five nonreceptor tyrosine kinases─BTK, ITK, BMX, TXK, and TEC─with key roles in immune signaling. Although BTK and ITK have been extensively studied, selective inhibitors for TEC, TXK, and BMX remain scarce. Recently, we identified 7-azaindole-based covalent BMX inhibitors with potent inhibitory activity and robust cellular target engagement but limited selectivity across TEC family members, especially BTK. Here, we describe a new generation of BMX inhibitors designed to exploit subtle structural differences between BMX and BTK by incorporating diverse N-acylamino substituents at the azaindole 5-position or variations at the linker and warhead. Our compounds display subnanomolar BMX potency and improved selectivity over BTK and other TEC kinases. Key compound 11i showed strong cellular target engagement, good in vitro metabolic stability, a favorable kinome profile, and rapid covalent inactivation kinetics, positioning it among the best BMX chemical probes currently available.

  • Open Access

    Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors

    by Xiaojun Julia Liang, Claudia Albertini, Thales Kronenberger, Ekaterina Shevchenko, Alexander Rasch, Benedict-Tilman Berger, Martin Schwalm, Lena Marie Berger, Andreas Krämer, Ricardo A. M. Serafim, et al.

    The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family comprises five non-receptor tyrosine kinases – BTK, ITK, BMX, TXK, and TEC – with key roles in immune signalling. Although BTK and ITK have been extensively studied, selective inhibitors for TEC, TXK, and BMX remain scarce. Recently, we identified 7-azaindole-based covalent BMX inhibitors with potent inhibitory activity and robust cellular target engagement but limited selectivity across TEC family members, especially BTK. Here, we describe a new generation of BMX inhibitors designed to exploit subtle structural differences between BMX and BTK by incorporating diverse N-acylamino substituents at the azaindole 5-position or variations at the linker and warhead. Our compounds display subnanomolar BMX potency and improved selectivity over BTK and other TEC kinases. Key compound 11i showed strong cellular target engagement, good in vitro metabolic stability, a favourable kinome profile, and rapid covalent inactivation kinetics, positioning it among the best BMX chemical probes currently available.

  • Open Access

    Riding toward Selectivity: Optimization of Covalent 7-Azaindole-Based BMX Kinase Inhibitors

    by Xiaojun Julia Liang, Claudia Albertini, Thales Kronenberger, Ekaterina Shevchenko, Alexander Rasch, Benedict-Tilman Berger, Martin Schwalm, Lena Marie Berger, Ricardo A. M. Serafim, Michael Forster, et al.

    The Tyrosine Kinase Expressed in Hepatocellular Carcinoma (TEC) family comprises five nonreceptor tyrosine kinases – BTK, ITK, BMX, TXK, and TEC – which play key roles in immunological signal transduction. Although BTK and ITK have been extensively studied, selective inhibitor development for TEC, TXK, and BMX remains scarce. In a recent study, we identified a new class of covalent BMX inhibitors with a 7-azaindole core. These compounds exhibit potent inhibitory activity and robust cellular target engagement but had limited selectivity across TEC family members, especially BTK, which is the closest relative of BMX. Here, we describe the next generation of BMX inhibitors that incorporate diverse N-acylamino substituents at the azaindole 5-position or variations in the linker and warhead region. These modifications were designed to exploit subtle structural differences between BMX and BTK in the pocket behind the gatekeeper residue as well as in the front pocket. Our compounds display excellent BMX potency in the sub-nanomolar range along with improved selectivity against BTK and other TEC family kinases. We identified compound 11i as a new BMX lead compound with strong cellular target engagement, good in vitro metabolic stability, a favourable kinome profile, and fast covalent inactivation kinetics. These properties position compound 11i among the best BMX chemical probes currently available.

  • Open Access

    Design, Synthesis, and Molecular Evaluation of SNAr‐Reactive N‐(6‐Fluoro‐3‐Nitropyridin‐2‐yl)Isoquinolin‐3‐Amines as Covalent USP7 Inhibitors Reveals an Unconventional Binding Mode

    by Larissa N. Ernst, Jason Stahlecker, Finn Mier, Ricardo A. M. Serafim, Valentin R. Wydra, Benedikt Masberg, Simon J. Jaag, Cornelius Knappe, Michael Lämmerhofer, Thilo Stehle, et al.

    The cysteine protease ubiquitin‐specific protease 7 (USP7), also known as herpes‐associated ubiquitin‐specific protease (HAUSP), has gained increasing attention in recent years due to its proven overexpression in several cancer types and its role in tumorigenesis. Herein, after a design based on molecular docking experiments, we report the synthesis of a series of mildly electrophilic compounds that covalently modify the catalytic cysteine 223 in USP7 through a nucleophilic aromatic substitution (SNAr) reaction. The compounds were first evaluated using differential scanning fluorimetry (DSF) to describe their influence on the melting temperature of native and mutant USP7 variants. Furthermore, the possible formation of a covalent bond was analyzed using intact protein mass spectrometry (MS). For promising derivatives, IC50 values were determined in an enzyme activity assay to confirm an inhibitory effect on USP7. Finally, a co‐crystal structure revealed that the prototype compound (7a) arylates the catalytic cysteine in the apo form of USP7 via an unconventional binding mode near the catalytic triad. The synthesis and biological evaluation of this compound series provides valuable structure–activity relationships (SAR) and reveals an interesting and unprecedented binding mode, thus providing a basis for improving USP7 inhibitors.


  • Open Access

    High-Quality In Vivo Chemical Probes for Protein Kinases Disclosed in 2024

    by Ricardo A. M. Serafim, Matthias Gehringer

    Protein kinases are highly relevant drug targets, yet a significant fraction of the human kinome remains underexplored. Highly potent and selective small-molecule inhibitors used as chemical probes are invaluable tools for enabling the validation and translation of new kinase targets. This review provides an overview and analysis of the high-quality in vivo chemical probes for protein kinases published and deposited at the Chemical Probes Portal in the year 2024. We discuss the design strategies, molecular mechanism of action, details of their use in vitro and in vivo, as well as their application in target (in)-validation. We also highlight the importance of wisely selecting chemical probes and encourage best practices in using such tool compounds.


  • Open Access

    Go for Gold: Development of a Scalable Synthesis of [1‐(Ethoxycarbonyl)cyclopropyl] Triphenylphosphonium Tetrafluoroborate, a Key Reagent to Explore Covalent Monopolar Spindle 1 Inhibitors

    by Leon Rebhan, Rebekka Fürst, Dieter Schollmeyer, Ricardo A. M. Serafim, Matthias Gehringer

    Covalent approaches have resurged in drug discovery and chemical biology during the last decade. So‐called targeted covalent inhibitors typically show a strong and persistent drug–target interaction as well as a high degree of selectivity. In our research group, RMS‐07 (8) , a First‐in‐Class covalent inhibitor of the protein kinase threonine tyrosine kinase (TTK)/monopolar spindle 1, which shows promising results in a variety of different solid cancer cell types and will be further optimized in terms of covalent binding kinetics, has recently been developed. However, synthetic accessibility is restricted by a high price and limited availability of [1‐(ethoxycarbonyl)cyclopropyl] triphenylphosphonium tetrafluoroborate ( 10 ), a key reagent required to assemble the tricyclic core scaffold in a Wittig‐type cyclization reaction. This reagent is also described as a valuable synthon for the synthesis of a range of ring systems with interesting applications in medicinal chemistry. However, reliable procedures for its large‐scale synthesis are scarce. Only one prior report describes the synthesis of reagent 10 , and it contains limited experimental details, making it challenging to reproduce and scale up. Herein, a concise and reproducible decigram‐scale synthetic protocol for accessing key reagent 10 is described.


  • Novel Dihydropteridinone Derivatives As Potent Inhibitors of the Understudied Human Kinases Vaccinia-Related Kinase 1 and Casein Kinase 1δ/ε

    by Fernando H. de Souza Gama, Luiz A. Dutra, Michael Hawgood, Caio Vinícius dos Reis, Ricardo A. M. Serafim, Marcos A. Ferreira, Bruno V. M. Teodoro, Jéssica Emi Takarada, André S. Santiago, Dimitrios-Ilias Balourdas, et al.

    Vaccinia-related kinase 1 (VRK1) and the δ and ε isoforms of casein kinase 1 (CK1) are linked to various disease-relevant pathways. However, the lack of tool compounds for these kinases has significantly hampered our understanding of their cellular functions and therapeutic potential. Here, we describe the structure-based development of potent inhibitors of VRK1, a kinase highly expressed in various tumor types and crucial for cell proliferation and genome integrity. Kinome-wide profiling revealed that our compounds also inhibit CK1δ and CK1ε. We demonstrate that dihydropteridinones 35 and 36 mimic the cellular outcomes of VRK1 depletion. Complementary studies with existing CK1δ and CK1ε inhibitors suggest that these kinases may play overlapping roles in cell proliferation and genome instability. Together, our findings highlight the potential of VRK1 inhibition in treating p53-deficient tumors and possibly enhancing the efficacy of existing cancer therapies that target DNA stability or cell division.


  • Chemical Probes for Understudied Kinases: Challenges and Opportunities

    by Ricardo A. M. Serafim, Jonathan M. Elkins, William J. Zuercher, Stefan A. Laufer, Matthias Gehringer

    Over 20 years after the approval of the first-in-class protein kinase inhibitor imatinib, the biological function of a significant fraction of the human kinome remains poorly understood while most research continues to be focused on few well-validated targets. Given the strong genetic evidence for involvement of many kinases in health and disease, the understudied fraction of the kinome holds a large and unexplored potential for future therapies. Specific chemical probes are indispensable tools to interrogate biology enabling proper preclinical validation of novel kinase targets. In this Perspective, we highlight recent case studies illustrating the development of high-quality chemical probes for less-studied kinases and their application in target validation. We spotlight emerging techniques and approaches employed in the generation of chemical probes for protein kinases and beyond and discuss the associated challenges and opportunities.


  • Discovery of a Potent Dual SLK/STK10 Inhibitor Based on a Maleimide Scaffold

    by Ricardo A. M. Serafim, Fiona J. Sorrell, Benedict-Tilman Berger, Ross J. Collins, Stanley N. S. Vasconcelos, Katlin B. Massirer, Stefan Knapp, James Bennett, Oleg Fedorov, Hitesh Patel, et al.

    SLK (STE20-like kinase) and STK10 (serine/threonine kinase 10) are closely related kinases whose enzymatic activity is linked to the regulation of ezrin, radixin, and moesin function and to the regulation of lymphocyte migration and the cell cycle. We identified a series of 3-anilino-4-arylmaleimides as dual inhibitors of SLK and STK10 with good kinome-wide selectivity. Optimization of this series led to multiple SLK/STK10 inhibitors with nanomolar potency. Crystal structures of exemplar inhibitors bound to SLK and STK10 demonstrated the binding mode of the inhibitors and rationalized their selectivity. Cellular target engagement assays demonstrated the binding of the inhibitors to SLK and STK10 in cells. Further selectivity analyses, including analysis of activity of the reported inhibitors against off-targets in cells, identified compound 31 as the most potent and selective inhibitor of SLK and STK10 yet reported.


  • Open Access

    Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor

    by Ricardo Serafim, André Santiago, Caio dos Reis, Jessica Takarada, Priscila Mezzomo, Katlin Massirer, Martin P. Schwalm, Mark Kudolo, Stefan Gerstenecker, Apirat Chaikuad, et al.

    Monopolar spindle kinase 1 (MPS1/TTK) is a key element of the mitotic checkpoint securing proper chromosome segregation. It is being evaluated as a target in the treatment of aggressive tumors such as triple-negative breast cancer with several reversible inhibitors currently undergoing clinical trials. While long drug–target residence times have been suggested to be beneficial in the context of therapeutic MPS1 inhibition, no irreversible inhibitors are known. Here we present the design and characterization of the first irreversible covalent MPS1 inhibitor RMS-07 targeting a cysteine (Cys604) in the kinase's hinge region present only in few other protein kinases. The compound showed excellent MPS1 inhibitory potency and high selectivity against all protein kinases harboring an equivalent cysteine as well as in a larger differential scanning fluorimetry-based screening panel. Covalent binding was confirmed by mass spectrometry and X-ray crystal structure. We expect this tool compound to open new avenues for the design of MPS1-specific covalent chemical probes or drugs.